Sign in Subscribe

Neurocrine Biosciences

Soleno Therapeutics Presents New VYKAT® XR (diazoxide choline) Data at ENDO 2026 Demonstrating Meaningful and Durable Improvements in Hyperphagia and Behavioral Symptoms in Prader-Willi Syndrome Following Randomized Withdrawal Period

Soleno Therapeutics Presents New VYKAT® XR (diazoxide choline) Data at ENDO 2026 Demonstrating Meaningful and Durable Improvements in Hyperphagia and Behavioral Symptoms in Prader-Willi Syndrome Following Randomized Withdrawal Period

* Participants who resumed VYKAT XR following a 16-week randomized withdrawal period demonstrated improvements in hyperphagia and behavioral symptoms as early as Week 13, with benefits continuing through 2 years * VYKAT XR demonstrated statistically significant and sustained improvements in hyperphagia and Prader-Willi syndrome-related behaviors for up to 3
Neurocrine Biosciences
Neurocrine Biosciences Presents First Retrospective Case Series of CRENESSITY® (crinecerfont) in Patients with Classic Congenital Adrenal Hyperplasia Due to 11β‑Hydroxylase Deficiency at ENDO 2026

Neurocrine Biosciences Presents First Retrospective Case Series of CRENESSITY® (crinecerfont) in Patients with Classic Congenital Adrenal Hyperplasia Due to 11β‑Hydroxylase Deficiency at ENDO 2026

* Androstenedione and other adrenal hormone levels in 11β‑hydroxylase-deficient patients improved substantially after initiation of CRENESSITY, with >90% median reductions in 11-deoxycortisol and 11-deoxycorticosterone * Nearly all patients (14/15) reduced their total glucocorticoid dose with CRENESSITY, and 2 of 5 patients on antihypertensive medications reduced or
Neurocrine Biosciences
Neurocrine Biosciences Presents New Two-Year CRENESSITY® (crinecerfont) Data Demonstrating Improvements in Cardiometabolic Outcomes in Adults with Classic Congenital Adrenal Hyperplasia at ENDO 2026

Neurocrine Biosciences Presents New Two-Year CRENESSITY® (crinecerfont) Data Demonstrating Improvements in Cardiometabolic Outcomes in Adults with Classic Congenital Adrenal Hyperplasia at ENDO 2026

* Two-year CRENESSITY data in adults showed improvements in cardiometabolic outcomes of insulin resistance, body composition and body weight alongside sustained reductions in glucocorticoid dose * Among participants who were overweight or obese at baseline, 37% achieved >5% reduction in body weight at 2 years, and 43% of those with
Neurocrine Biosciences
Neurocrine Biosciences Presents New Clinically Meaningful Response Data on Treatment of Tardive Dyskinesia, Reinforcing the Efficacy of INGREZZA® (valbenazine) Capsules Across a Broad Range of Patients

Neurocrine Biosciences Presents New Clinically Meaningful Response Data on Treatment of Tardive Dyskinesia, Reinforcing the Efficacy of INGREZZA® (valbenazine) Capsules Across a Broad Range of Patients

* New 48-week KINECT® 4 post-hoc analysis shows 94% of participants treated with INGREZZA achieved either symptomatic remission or a clinically meaningful response (≥30% reduction from baseline in Abnormal Involuntary Movement Scale total score); INGREZZA is the only vesicular monoamine transporter 2 (VMAT2) inhibitor to demonstrate clinical remission in
Neurocrine Biosciences
Neurocrine Biosciences Presents New Data Highlighting Functional and Socio-emotional Improvements with INGREZZA® (valbenazine) Capsules in Individuals with Tardive Dyskinesia and Intellectual and Developmental Disabilities

Neurocrine Biosciences Presents New Data Highlighting Functional and Socio-emotional Improvements with INGREZZA® (valbenazine) Capsules in Individuals with Tardive Dyskinesia and Intellectual and Developmental Disabilities

* Nearly all individuals with intellectual and developmental disabilities experienced improvement in tardive dyskinesia severity after starting INGREZZA, and of those, 89% experienced improvement within 4 weeks  * Clinician-reported data showed improvements in key aspects of daily life following INGREZZA treatment in nearly all patients with tardive dyskinesia and intellectual and
Neurocrine Biosciences
Neurocrine Biosciences to Present New Two‑Year CRENESSITY® (crinecerfont) Data on Key Clinical and Patient‑Reported Outcome Measures at ENDO 2026

Neurocrine Biosciences to Present New Two‑Year CRENESSITY® (crinecerfont) Data on Key Clinical and Patient‑Reported Outcome Measures at ENDO 2026

* Analyses span adult and pediatric populations with classic congenital adrenal hyperplasia (CAH) and reflect longer-term clinical outcomes relevant to disease management across lifespan and care continuum * New data demonstrate the effect of CRENESSITY on long-term androgen control and glucocorticoid dose reduction and associated clinical outcomes * Data from cross-
Neurocrine Biosciences